8NE.F LISATA THERAP.INC.DL-001
- Market cap
- EUR 10.3M
- P/E
- -
- P/B
- 1.21x
- ROE
- -180.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8NE.F undervalued?
Graham numberThe Graham number of LISATA THERAP.INC.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LISATA THERAP.INC.DL-001 fundamental analysis
No fundamental analysis for LISATA THERAP.INC.DL-001 yet.
LISATA THERAP.INC.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of …
Full company profileLISATA THERAP.INC.DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LISATA THERAP.INC.DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 1.00M | 170K | 0.00 |
| Operating Income | -29.1M | -57.6M | -25.7M | -22.4M | -18.2M | -17.9M |
| EBITDA | - | -57.5M | -25.5M | -22.2M | -18.1M | -17.9M |
| Net Income | -27.5M | -54.2M | -20.8M | -20.0M | -16.6M | -14.8M |
| EPS | -6.89 | -6.86 | -2.56 | -2.38 | -1.88 | -1.63 |
| Balance Sheet | ||||||
| Total Assets | 97.0M | 73.0M | 54.7M | 35.0M | 17.7M | 11.0M |
| Total Liabilities | 5.01M | 6.71M | 6.80M | 5.69M | 3.14M | 3.04M |
| Shareholders' Equity | 92.3M | 66.6M | 48.1M | 29.6M | 14.9M | 8.24M |
| Cash & Short-term Investments | 24.6M | 32.2M | 22.6M | 16.2M | 16.0M | 10.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -22.2M | -21.2M | -20.0M | -19.4M | -15.9M | -11.5M |
| Capital Expenditure | 60.0K | 285K | 0.00 | 0.00 | 28.0K | 0.00 |
| Free Cash Flow | -22.3M | -21.5M | -20.0M | -19.4M | -16.0M | -11.5M |
| Ratios | ||||||
| ROE | -29.8% | -81.4% | -43.3% | -67.6% | -111.7% | -180.0% |
| ROA | -28.3% | -74.2% | -38.1% | -57.1% | -93.5% | -134.5% |
| Net Profit Margin | - | - | - | -1,998.5% | -9,756.5% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LISATA THERAP.INC.DL-001 dividends
LISATA THERAP.INC.DL-001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on Sep 15, 2022.
Who owns LISATA THERAP.INC.DL-001
- Insiders 20.57%
- Institutions 11.18%
- Public & others 68.25%
- Shares outstanding 10.8M
- Free float 6.91M
LISATA THERAP.INC.DL-001 company profile
- Company name
- LISATA THERAP.INC.DL-001
- Ticker
- 8NE.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 110 Allen Road, Basking Ridge, NJ, United States, 07920
- Phone
- 908 842 0100
- Website
- lisata.com
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
LISATA THERAP.INC.DL-001 management
4- Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO & Director · born 1957
- Mr. James NiscoSVP of Finance and Treasury & Chief Accounting Officer · born 1971
- Dr. Joshua Lehrer-Graiwer FACC, M.D.President & COO · born 1974
- Mr. Tariq ImamHead of Human Resources, Senior VP of Business Development & Operations and General Counsel · born 1983